ArticleFrontiers in immunology2026
Fc gamma receptor binding modulates IgG clearance in cancer cachexia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Scavenger Function of LSECs, a Regulator of Liver Diseases.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background: Patients with cancer-cachexia display a general resistance to Immune Checkpoint Inhibitor (ICI) therapy, as well as an elevated baseline catabolic clearance (CL) of ICIs, which serves as a prognostic indicator of overall survival independent of dose and drug exposure. Increased rate of ICI CL is present in the Lewis Lung Carcinoma (LLC) murine model of cachexia, but absent in the non-cachectic MC38 model. Fc-Gamma Receptors (FcγRs) bind the Fc portion of antibodies and can impact ICI anti-tumor efficacy. Methods: A pharmacokinetic study of human IgG1 (hIgG1) and hIgG1 with D265A (D265A) mutation, to abrogate all FcγR binding, was performed in mice that were either LLC tumor bearing (TB) or tumor free (TF). Immunofluorescence studies using fluorescence conjugated anti-human IgG were conducted to detect and localize infused hIgG1 in the mouse liver. To further investigate, FcγRIIb knockout mice were utilized in pharmacokinetic studies with hIgG. Results: CL of both IgG1 and D265A significantly increased in LLC TB mice compared to TF controls, however the CL of D265A was significantly lower compared to hIgG1 in LLC TB mice. Immunofluorescence image of mouse livers portrays colocalization of the administered hIgG1 and FcγRIIb in liver sinusoidal endothelial cells (LSEC), as well as upregulated hepatic expression of FcγRIIb in LLC TB. However, hIgG1 CL was unaffected by whole body knockout of FcγRIIb. Conclusion: Reduced CL of D265A versus IgG1 in LLC TB mice, but not TF mice, suggests FcγRs are involved in catabolic CL of IgG antibodies in the presence of LLC tumors and cancer cachexia. This suggest that in the presence of LLC tumors, changes in FcγR expression and/or function lead to significantly altered antibody CL mediated by FcγR. This apparent role of FcγRs in antibody catabolism cannot be solely explained by FcγRIIb, but instead suggests the significance of other FcγRs in cachexia-associated increases in antibody CL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.